«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

26卷

期数:

2020年01期

页码:

28-31

栏目:

临床医学

出版日期:

2020-04-06

文章信息/Info

Title:

Effects of Cisapride on symptoms of digestive and gastrointestinal hormones in patients with different dialysis modes

文章编号:

1006-8147(2020)01-0028-04

作者:

王冰月¹; 2; 姜埃利¹; 李春红²; 徐 婧²; 董 昆²; 田 洁²; 魏 肃²; 贾 茹²

（1.天津医科大学第二医院肾脏病与血液净化中心，天津300211；2.天津市第三中心医院肾病科，天津300170）

Author(s):

WANG Bing-yue¹; 2; JIANG Ai-li¹; LI Chun-hong¹; XU Jing²; DONG Kun²; TIAN Jie²; WEI Su²; JIA Ru²

（1.Kidney Disease and Blood Purification Center, The Second Hospital, Tianjin Medical University, Tianjin 300211, China；2.Department of Nephropathy, The Third Central Hospital of Tianjin, Tianjin 300170, China)

关键词:

西沙必利; 血液透析; 腹膜透析; 消化道症状; 胃肠激素

Keywords:

Cisapride; hemodialysis; peritoneal dialysis;  gastrointestinal symptoms; gastrointestinal hormones

分类号:

R692

DOI:

-

文献标志码:

A

摘要:

目的：研究西沙必利对HD和PD患者消化道症状及胃肠激素的影响。方法：选取透析患者120例作为研究对象，同期选择40位健康人作为对照组，在给予基础疾病的常规治疗基础上加用西沙必利治疗，对比血清生长抑素（SS）、胃动素（MOT）及血管活性肠肽（VIP）水平，以及消化道症状、胃肠激素和部分生化指标的变化。结果：治疗后，HD组和PD组患者消化道症状评分显著低于治疗前（P＜0.05），治疗后PD组在腹胀和便秘症状得分仍高于HD组；HD组和PD组治疗前后SS和VIP无显著变化（P＞0.05），MOT显著下降（P＜0.05）；PD组和HD组治疗前后BUN、Scr、Hb和kt/v对比无显著差异（P＞0.05），而PD组ALB水平治疗后较治疗前升高（P＜0.05）。研究组胃肠激素水平明显高于健康对照组。结论：透析患者都普遍存在消化道症状，且存在明显的胃肠激素蓄积，在常规基础疾病治疗的基础上加用西沙必利可以改善其消化道症状效果，同时降低患者血清胃动素含量。

Abstract:

Objective: To study the therapeutic effect of Cisapride on symptoms of digestive and gastrointestinal hormones in different dialysis patients. Methods: There were 120 cases of dialysis patients being selected as the study group in this paper , and they were additionally treated with cisapride on the base of being given routine treatment of the underlying disease. 40 healthy peoples were selected as the control group. The gastrointestinal symptoms, serum somatostatin（SS）, motilin（MOT）andvasoactive intestinal peptide（VIP）and renal function and biochemical indexes were compared before and after treatment in HD group and PD group. Gastrointestinal hormones were compared with the control group. Results: The score of gastrointestinal symptoms were significantly lower after treatment than before (P＜0.05). After treatment, the scores of abdominal distension and constipation in PD group were still higher than those in HD group;There was no significant change between before and after treatment in BUN、Scr、Hb、kt/v、SS and VIP in PD group and HD group(P＞0.05)，but the MOT were decreased significantly(P＜0.05) ，and the level of ALB in PD group increased after treatment (P＜0.05). The level of gastrointestinal hormones in the study group was significantly higher than those in the healthy control group. Conclusion: gastrointestinal symptoms are common in dialysis patients, and there is obvious accumulation of gastrointestinal hormones, which leads to gastrointestinal dysfunction. Conventional treatment combined with Cisapride can improve the effect of gastrointestinal symptoms in these patients，while reducing serum motilin levels.

参考文献/References:

[1] Salamon K, Woods J, Paul E, et al. Peritoneal dialysis patients have higher prevalence of gastrointestinal symptoms than hemodialysis patients[J]． J Ren Nutr，2013(23): 114
[2] Nand N, Malhotra P, Bala R. Evaluation of upper gastrointestinal symptoms and effect of different modalities of treatment in patients of chronic kidney disease[J]. J Ind Acad Clin Med, 2014, 15(3):182
[3] 李西睦, 孙晓慧, 喻广娟,等. 多潘立酮、西沙必利及小剂量红霉素治疗早产儿喂养不耐受临床效果比较[J]. 山东医药, 2010, 50(43):104
[4] Dong R, Guo Z Y, Ding J R, et al. Gastrointestinal symptoms: A comparison between patients undergoing peritoneal dialysis and hemodialysis[J]. World J Gastroenterol, 2014, 20(32): 11370
[5] Dejardin A, Robert A, Goffin E. Intraperitoneal pressure in PD patients:relationship tointraperitoneal volume, body size and PDrelated complications[J]． Nephrol Dial Transplant, 2007,22 (5):1437
[6] Van V, Schoonjans R S, Struijk D G, et al. Influence ofdialysate on gastric emptying time in peritoneal dialysis patients[J]． Perit Dial Int，2002，22(1): 32
[7] Bacci M, Ｒusso F, Carvalho G, et al. Endoscopic alterations in a cohort of hemodialysis patients: a cross-sectional study[J]. Int J Gen Med, 2014, 16(7): 459
[8] Santos P R, Monteiro D L, de Paula P H, et al. Volaemic status and dyspepsia in end-stage renal disease patients[J]. Nephrology(Carlton), 2015, 20(8): 519
[9] Manley K J. Saliva composition and upper gastrointestinal symptoms in chronic kidney disease[J]. Kidney Res Clin Pract, 2014, 40(3):172
[10] 贾佑铎, 郭兆安. 慢性肾衰竭消化系统症状发病机制及治疗研究新进展[J]. 中国中西医结合肾病杂志, 2014,15(10):936
[11] 张静, 郭立华, 姜琦, 等． 胃肠肽激素在慢性肾功能衰竭患者行血液透析后的变化影响[J]. 现代消化及介入诊疗, 2016,21(1):135
[12] 颜怀荣, 东阳, 程悦, 等. 血液透析联合血液灌流治疗对慢性肾衰患者微炎症状态的影响[J]. 西部医学, 2015,27(2):218
[13] Pierre P, Peeters T L. Motilin[J]. Curr Opin Endocrinol Diab Obes, 2008,15(1):54
[14] 张彤彦, 王雁, 袁申元,等. 西沙比利对糖尿病胃轻瘫患者胃运动功能及血浆胃动素的影响[J]. 首都医科大学学报,2001,22(3):236
[15] Tatsuta M, Iishi H, Nakaizumi A, et al. Effect of treatment with cisapride alone or in combination with domperidone on GE and gastro-intestinal symptoms in dyspeptics[J]. Aliment Pharmacol Therapeut, 2007, 6(2):221
[16] Talley N J, Walker M M, Holtmann G． Functional dyspepsia[J]． Curr Opin Gastroenterol, 2016, 32(6):467

相似文献/References:

[1]梁霄,杨定位,武子霞,等.非布司他对无症状高尿酸血症透析患者心脑血管事件及血清学指标的影响[J].天津医科大学学报,2021,27(06):564.
　LIANG Xiao,YANG Ding-wei,WU Zi-xia,et al.The study of febuxostat on cardiovascular and cerebrovascular events and serological indexes of asymptomatic hyperuricemia patients with hemodialysis[J].Journal of Tianjin Medical University,2021,27(01):564.

备注/Memo

备注/Memo:

作者简介 王冰月（1976-），女，副主任医师，博士在读，研究方向：肾脏病与血液净化；通信作者：姜埃利，E-mail：carlos_j@126.com。

常用功能

更新日期/Last Update: 2020-04-16